UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial

Clinical infectious diseases, 2019-11, Vol.69 (11), p.1856-1867

2019

Volltextzugriff (PDF)

Anti-inflammatory activity of lefamulin versus azithromycin and dexamethasone in vivo and in vitro in a lipopolysaccharide-induced lung neutrophilia mouse model

PloS one, 2021-09, Vol.16 (9), p.e0237659

2021

Volltextzugriff (PDF)

In Vivo Immune-Modulatory Activity of Lefamulin in an Influenza Virus A (H1N1) Infection Model in Mice

International journal of molecular sciences, 2024-05, Vol.25 (10), p.5401

2024

Volltextzugriff (PDF)

Pharmacodynamic evaluation of lefamulin in the treatment of gonorrhea using a hollow fiber infection model simulating Neisseria gonorrhoeae infections

Frontiers in pharmacology, 2022-11, Vol.13, p.1035841-1035841

2022

Volltextzugriff (PDF)

Pharmacokinetics/pharmacodynamics of lefamulin in a neutropenic murine pneumonia model with Staphylococcus aureus and Streptococcus pneumoniae

Journal of antimicrobial chemotherapy, 2019-04, Vol.74 (Supplement_3), p.iii11-iii18

2019

Volltextzugriff (PDF)

Tissue Distribution of [ 14 C]-Lefamulin into the Urogenital Tract in Rats

Antimicrobial agents and chemotherapy, 2022-08, Vol.66 (8), p.e0035522

2022

Volltextzugriff (PDF)

In vivo pharmacodynamics of lefamulin, the first systemic pleuromutilin for human use, in a neutropenic murine thigh infection model

Journal of antimicrobial chemotherapy, 2019-04, Vol.74 (Supplement_3), p.iii5-iii10

2019

Volltextzugriff (PDF)

Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2019-11, Vol.322 (17), p.1661

2019

Volltextzugriff (PDF)

Prediction of lefamulin epithelial lining fluid penetration after intravenous and oral administration using Phase 1 data and population pharmacokinetics methods

Journal of antimicrobial chemotherapy, 2019-04, Vol.74 (Supplement_3), p.iii27-iii34

2019

Volltextzugriff (PDF)

Pharmacokinetics and tolerability of lefamulin following intravenous and oral dosing

Journal of antimicrobial chemotherapy, 2019-04, Vol.74 (Supplement_3), p.iii19-iii26

2019

Volltextzugriff (PDF)

Safety and Pharmacokinetics Following Oral or Intravenous Lefamulin in Adults With Cystic Fibrosis

Clinical therapeutics, 2024-02, Vol.46 (2), p.96-103

2024

Volltextzugriff (PDF)

Pharmacokinetics and safety of lefamulin after single intravenous dose administration in subjects with impaired‐hepatic function

Pharmacotherapy, 2021-05, Vol.41 (5), p.457-462

2021

Volltextzugriff (PDF)

Pharmacokinetics and safety of lefamulin after single intravenous dose administration in subjects with impaired renal function and those requiring hemodialysis

Pharmacotherapy, 2021-05, Vol.41 (5), p.451-456

2021

Volltextzugriff (PDF)

Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia

Journal of antimicrobial chemotherapy, 2019-04, Vol.74 (Supplement_3), p.iii35-iii41

2019

Volltextzugriff (PDF)

Tissue Distribution of 14C-Lefamulin into the Urogenital Tract in Rats

Antimicrobial agents and chemotherapy, 2022-08, Vol.66 (8), p.e0035522

2022

Volltextzugriff (PDF)

Erratum to: Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial

Clinical infectious diseases, 2020-05, Vol.70 (11), p.2459-2459

2020

Volltextzugriff (PDF)

2189. Anti-inflammatory Activity of Lefamulin in a Mouse Model of Influenza Virus H1N1 Infection

Open forum infectious diseases, 2022-12, Vol.9 (Supplement_2)

2022

Volltextzugriff (PDF)

Efficacy of Lefamulin Against Staphylococcus aureus-Induced Bacteremia in a Neutropenic and Immunocompetent Murine Model

Open forum infectious diseases, 2017-10, Vol.4 (suppl_1), p.S471-S471

2017

Volltextzugriff (PDF)

LB6. Oral Lefamulin Is Safe and Effective in the Treatment of Adults With Community-Acquired Bacterial Pneumonia (CABP): Results of Lefamulin Evaluation Against Pneumonia (LEAP 2) Study

Open forum infectious diseases, 2018-11, Vol.5 (suppl_1), p.S761-S761

2018

Volltextzugriff (PDF)

Population Pharmacokinetic (PPK) Analysis for Lefamulin Using Phase 1 Data and Assessment of Optimal PK Sampling Strategies (OSS) for a Phase 3 Community-Acquired Bacterial Pneumonia (CABP) Study

Open forum infectious diseases, 2016-12, Vol.3 (suppl_1)

2016

Volltextzugriff (PDF)

Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Oral Lefamulin Dose Selection in the Treatment of Patients with Community-Acquired Bacterial Pneumonia (CABP)

Open forum infectious diseases, 2016-12, Vol.3 (suppl_1)

2016

Volltextzugriff (PDF)

Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment (TA) Analyses Supporting Lefamulin Dose Selection for the Treatment of Patients With Community-Acquired Bacterial Pneumonia (CABP)

Open forum infectious diseases, 2015-12, Vol.2 (suppl_1)

2015

Volltextzugriff (PDF)

793Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment (TA) Analyses Supporting Lefamulin Dose Selection for the Treatment of Patients With Community-Acquired Bacterial Pneumonia (CABP)

Open forum infectious diseases, 2015-12, Vol.2 (suppl_1), p.S231-S231

2015

Volltextzugriff (PDF)

1 – 23 von 23

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(22)

Publikationsform

Artikel
(23)

Sprache

Englisch
(23)

Erscheinungsjahr

n.n

Thema

Science & Technology
(14)
Life Sciences & Biomedicine
(13)
Pharmacology & Pharmacy
(10)
Microbiology
(7)
Infectious Diseases
(6)
Lefamulin
(6)
Humans
(5)
Pharmacokinetics
(5)
Pneumonia
(5)
Supplement Papers
(5)
Female
(4)
Intravenous Administration
(4)
Polycyclic Compounds
(4)
Administration, Intravenous
(3)
Animals
(3)
Antibiotics
(3)
Diterpenes - Administration & Dosage
(3)
Diterpenes - Adverse Effects
(3)
Diterpenes - Pharmacology
(3)
Diterpenes - Therapeutic Use
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial

Anti-inflammatory activity of lefamulin versus azithromycin and dexamethasone in vivo and in vitro in a lipopolysaccharide-induced lung neutrophilia mouse model

In Vivo Immune-Modulatory Activity of Lefamulin in an Influenza Virus A (H1N1) Infection Model in Mice

Pharmacodynamic evaluation of lefamulin in the treatment of gonorrhea using a hollow fiber infection model simulating Neisseria gonorrhoeae infections

Pharmacokinetics/pharmacodynamics of lefamulin in a neutropenic murine pneumonia model with Staphylococcus aureus and Streptococcus pneumoniae

Tissue Distribution of [ 14 C]-Lefamulin into the Urogenital Tract in Rats

In vivo pharmacodynamics of lefamulin, the first systemic pleuromutilin for human use, in a neutropenic murine thigh infection model

Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial

Prediction of lefamulin epithelial lining fluid penetration after intravenous and oral administration using Phase 1 data and population pharmacokinetics methods

Pharmacokinetics and tolerability of lefamulin following intravenous and oral dosing

Safety and Pharmacokinetics Following Oral or Intravenous Lefamulin in Adults With Cystic Fibrosis

Pharmacokinetics and safety of lefamulin after single intravenous dose administration in subjects with impaired‐hepatic function

Pharmacokinetics and safety of lefamulin after single intravenous dose administration in subjects with impaired renal function and those requiring hemodialysis

Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia

Tissue Distribution of 14C-Lefamulin into the Urogenital Tract in Rats

Erratum to: Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial

2189. Anti-inflammatory Activity of Lefamulin in a Mouse Model of Influenza Virus H1N1 Infection

Efficacy of Lefamulin Against Staphylococcus aureus-Induced Bacteremia in a Neutropenic and Immunocompetent Murine Model

LB6. Oral Lefamulin Is Safe and Effective in the Treatment of Adults With Community-Acquired Bacterial Pneumonia (CABP): Results of Lefamulin Evaluation Against Pneumonia (LEAP 2) Study

Population Pharmacokinetic (PPK) Analysis for Lefamulin Using Phase 1 Data and Assessment of Optimal PK Sampling Strategies (OSS) for a Phase 3 Community-Acquired Bacterial Pneumonia (CABP) Study

Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Oral Lefamulin Dose Selection in the Treatment of Patients with Community-Acquired Bacterial Pneumonia (CABP)

Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment (TA) Analyses Supporting Lefamulin Dose Selection for the Treatment of Patients With Community-Acquired Bacterial Pneumonia (CABP)

793Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment (TA) Analyses Supporting Lefamulin Dose Selection for the Treatment of Patients With Community-Acquired Bacterial Pneumonia (CABP)

Suchergebnisse filtern